Clinical trial
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant…
NCT00330369 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00330369 |
|---|---|
| Title | DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension |
| Official title | DORADO - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a… |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Darusentan, Darusentan Placebo |
| Enrollment | 352 |
| Start date | Jun 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | May 26, 2006 |
| Last update posted | Mar 18, 2014 |
| Countries | Argentina, Brazil, Canada, Denmark, France, Germany, Italy, Spain, Sweden, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: